NCT05875805 A Telehealth Advance Care Planning Intervention
| NCT ID | NCT05875805 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Myeloid Malignancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 207 participants |
| Start Date | 2024-05-20 |
| Primary Completion | 2027-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 207 participants in total. It began in 2024-05-20 with a primary completion date of 2027-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.
Eligibility Criteria
Inclusion and Exclusion Criteria for Patients Inclusion criteria: * Age ≥60 years * A diagnosis of AML, MDS, and similar myeloid malignancies (including but not limited to MDS/MPN overlap syndrome, myelofibrosis) * Being managed in the outpatient settings * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Caregivers Inclusion criteria: * Age ≥18 years * Selected by patient when asked if there is a "family member, partner, friend, or caregiver with whom you discuss or who can be helpful in health-related matters" * Able to provide informed consent * English-speaking Exclusion criteria: \- None Inclusion and Exclusion Criteria for Oncology Providers Inclusion criteria: \- Oncologists and/or APPs who will be conducting the telehealth-delivered ACP visit Exclusion criteria: \- None
Contact & Investigator
Kah Poh Loh
PRINCIPAL INVESTIGATOR
University of Rochester
Frequently Asked Questions
Who can join the NCT05875805 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Myeloid Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05875805 currently recruiting?
Yes, NCT05875805 is actively recruiting participants. Contact the research team at Kahpoh_Loh@URMC.Rochester.edu for enrollment information.
Where is the NCT05875805 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT05875805 clinical trial?
NCT05875805 is sponsored by University of Rochester. The principal investigator is Kah Poh Loh at University of Rochester. The trial plans to enroll 207 participants.